EDITAS MEDICINE, INC. Net Cash Provided by (Used in) Financing Activities, Continuing Operations
EDITAS MEDICINE, INC. (EDIT) reported Net Cash Provided by (Used in) Financing Activities, Continuing Operations of $97.09 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-15.
Discontinued › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations · last filed 2017-05-15
- EDITAS MEDICINE, INC. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2017-03-31 was $97.09M, a 1.14% decline year-over-year.
- EDITAS MEDICINE, INC. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2016-12-31 was -$538.00K.
- EDITAS MEDICINE, INC. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2016-09-30 was -$22.00K, a 100.02% decline year-over-year.
- EDITAS MEDICINE, INC. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2016-06-30 was -$494.00K, a 102.25% decline year-over-year.
- EDITAS MEDICINE, INC. net cash provided by (used in) financing activities, continuing operations for fiscal 2016 was $97.16M, a 30.30% decline from fiscal 2015.
- EDITAS MEDICINE, INC. net cash provided by (used in) financing activities, continuing operations for fiscal 2015 was $139.39M, a 654.16% increase from fiscal 2014.
- EDITAS MEDICINE, INC. net cash provided by (used in) financing activities, continuing operations for fiscal 2014 was $18.48M.
| Period end | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-03-31 | $97.09M 10-Q · filed 2017-05-15 | $96.56M derived: sum of 2 quarters · filed 2017-05-15 | $96.53M derived: sum of 3 quarters · filed 2017-05-15 | $96.04M derived: sum of 4 quarters · filed 2017-05-15 |
| 2016-12-31 | -$538.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-03 | -$560.00K derived: sum of 2 quarters · filed 2017-03-03 | -$1.05M derived: sum of 3 quarters · filed 2017-03-03 | $97.16M 10-K · filed 2017-03-03 |
| 2016-09-30 | -$22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$516.00K derived: sum of 2 quarters · filed 2016-11-09 | $97.70M 10-Q · filed 2016-11-09 | $93.95M derived: sum of 4 quarters · filed 2017-05-15 |
| 2016-06-30 | -$494.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $97.72M 10-Q · filed 2016-08-10 | $93.97M derived: sum of 3 quarters · filed 2017-05-15 | $214.36M derived: sum of 4 quarters · filed 2017-05-15 |
| 2016-03-31 | $98.22M 10-Q · filed 2017-05-15 | $94.46M derived: sum of 2 quarters · filed 2017-05-15 | $214.85M derived: sum of 3 quarters · filed 2017-05-15 | $236.81M derived: sum of 4 quarters · filed 2017-05-15 |
| 2015-12-31 | -$3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-03 | $116.64M derived: sum of 2 quarters · filed 2017-03-03 | $138.60M derived: sum of 3 quarters · filed 2017-03-03 | $139.39M 10-K · filed 2017-03-03 |
| 2015-09-30 | $120.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $142.35M derived: sum of 2 quarters · filed 2016-11-09 | $143.14M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $21.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $22.75M 10-Q · filed 2016-08-10 | ||
| 2015-03-31 | $791.00K 10-Q · filed 2016-05-13 | |||
| 2014-12-31 | $18.48M 10-K · filed 2017-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |